A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
Trial Summary
What is the purpose of this trial?
This trial tests ADX-629, an oral medication, on patients with chronic cough that doesn't respond to usual treatments or has no known cause. It aims to see if the medication can safely and effectively reduce their coughing symptoms.
Will I have to stop taking my current medications?
The trial requires you to stop taking antitussive medications (cough suppressants) for the duration of the study. If you are currently taking an ACE inhibitor, you must have stopped it at least 3 months before the screening.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period 1
Participants receive either ADX-629 or placebo orally twice a day for 14 days
Washout
A washout period between treatment periods to clear the drug from the system
Treatment Period 2
Participants crossover to receive the alternate treatment (ADX-629 or placebo) for 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ADX-629
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aldeyra Therapeutics, Inc.
Lead Sponsor